Every weekday, the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday 's key moments. 1. Stocks rose Wednesday following President Donald Trump's address at the World Economic Forum, where he eased investor concerns by saying the U.S. wouldn't use force to acquire Greenland. "We had a remarkable resurgence [this morning]," said Jim Cramer, but he added the rally is being led by "the wrong tech," pointing to Micron , which is heavily tied to ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite moving lower on Wednesday.The Dow traded up 0.30% to 48,632.75 while the NASDAQ fell 0.06% to 22,940.77. The S&P 500 also rose, gaining, 0.16% to 6,807.83.Leading and Lagging SectorsEnergy shares gained by 2% on Wednesday.In trading on Wednesday, consumer staples stocks dipped by 0.5%.Top HeadlineJohnson & Johnson (NYSE:JNJ) on Wednesday reported better-than-expected fourth-quarter earnings.The company posted adjusted earnings of $2. ...

Full-year 2025 worldwide sales were $94.2 billion, up 5.3% operationally despite an approximate 620 basis point headwind from Stelara. U.S. growth was 6.9% and growth outside the U.S. was 3.4%. Acquisitions and divestitures contributed 110 basis points, driven primarily by the Intra-Cellular and Shockwave acquisitions.For the quarter, net earnings were $5.1 billion and diluted EPS was $2.10 versus $1.41 a year earlier. Adjusted net earnings were $6.0 billion and adjusted diluted EPS was $2.46, representing ...

Key Takeaways J&J posted Q4 EPS of $2.46, beating estimates, as earnings rose 20.6% year over year.JNJ's Innovative Medicines sales climbed 10%, driven by Darzalex, Tremfya and Erleada growth.Oncology drugs like Darzalex and Carvykti delivered strong gains, offsetting Stelara declines.Johnson & Johnson’s (JNJ) fourth-quarter 2025 earnings came in at $2.46 per share, which beat the Zacks Consensus Estimate of $2.43. Earnings rose 20.6% from the year-ago period.Adjusted earnings exclude intangible amortizatio ...

Market Analysis by covering: Johnson & Johnson. Read 's Market Analysis on Investing.com ...

JNJ stock price today: Johnson & Johnson (JNJ) stock fell on Wednesday even after the healthcare giant forecast 2026 sales and profit above Wall Street expectations, as legal concerns continue to weigh on the stock, as per a report.J&J Stock Today Slips Despite Strong 2026 Sales and Profit ForecastThe company said it expects 2026 operational sales of $99.5 billion to $100.5 billion, ahead of analysts’ estimates of $98.9 billion, as per a Reuters report citing LSEG data. Full-year 2026 profit is projected at ...

Johnson & Johnson (JNJ) stock tumbled Wednesday, though the company issued strong 2026 guidance, as Boston Scientific (BSX) and Medtronic (MDT) continue undercutting its electrophysiology business. Electrophysiology tools study the heart's rhythm. Pulsed field ablation, or PFA, is an electrophysiology tool that uses high-voltage electrical pulses to destroy problematic heart tissue, thus restoring normal rhythm for people with atrial fibrillation.… ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings call January 21, 2026 08:30 AM ET Company ParticipantsDarren Snellgrove - VP of Investor RelationsJohn Reed - EVP of Innovative Medicine and R and DJoaquin Duato - CEOJoseph Wolk - CFOJennifer Taubert - EVP and Worldwide Chairman of Innovative MedicineConference Call ParticipantsTerence Flynn - AnalystAlexandria Hammond - AnalystVamil Divan - AnalystJoanne Wuensch - AnalystChris Schott - AnalystShagun Singh - AnalystLarry Biegelsen - AnalystAsad Haider - Analyst ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings call January 21, 2026 08:30 AM ET Company ParticipantsDarren Snellgrove - VP of Investor RelationsJohn Reed - EVP of Innovative Medicine and R and DJoaquin Duato - CEOJoseph Wolk - CFOJennifer Taubert - EVP and Worldwide Chairman of Innovative MedicineConference Call ParticipantsTerence Flynn - AnalystAlexandria Hammond - AnalystVamil Divan - AnalystJoanne Wuensch - AnalystChris Schott - AnalystShagun Singh - AnalystLarry Biegelsen - AnalystAsad Haider - Analyst ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings call January 21, 2026 08:30 AM ET Speaker1Good morning and welcome to Johnson & Johnson's fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press star zero to reach the operator. I will now turn the con ...